X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5947) 5947
Newspaper Article (606) 606
Publication (323) 323
Book Review (144) 144
Newsletter (71) 71
Magazine Article (63) 63
Book Chapter (60) 60
Trade Publication Article (29) 29
Dissertation (9) 9
Transcript (8) 8
Conference Proceeding (6) 6
Book / eBook (4) 4
Reference (3) 3
Data Set (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4466) 4466
insulin (3981) 3981
index medicus (3614) 3614
diabetes (3262) 3262
hypoglycemic agents - therapeutic use (2721) 2721
endocrinology & metabolism (2580) 2580
diabetes mellitus, type 2 - drug therapy (2541) 2541
female (2201) 2201
male (2133) 2133
type 2 diabetes (2083) 2083
insulin - therapeutic use (2013) 2013
middle aged (1593) 1593
hypoglycemia (1518) 1518
insulin glargine (1445) 1445
glucose (1438) 1438
glycemic control (1425) 1425
hypoglycemic agents - administration & dosage (1331) 1331
aged (1139) 1139
adult (1105) 1105
diabetes mellitus (1096) 1096
diabetes therapy (1085) 1085
insulin - analogs & derivatives (1068) 1068
insulin - administration & dosage (1062) 1062
hyperglycemia (1014) 1014
care and treatment (1005) 1005
diabetes mellitus, type 1 - drug therapy (980) 980
diabetes mellitus, type 2 - blood (968) 968
blood glucose - metabolism (944) 944
hypoglycemic agents - adverse effects (935) 935
therapy (933) 933
treatment outcome (923) 923
internal medicine (781) 781
glargine (760) 760
research (728) 728
glycated hemoglobin a - metabolism (722) 722
blood glucose - drug effects (720) 720
pharmacology & pharmacy (700) 700
basal insulin (694) 694
metformin (694) 694
drug therapy (688) 688
insulin, long-acting (683) 683
mellitus (679) 679
nph insulin (672) 672
medicine & public health (660) 660
risk factors (660) 660
type 1 diabetes (636) 636
clinical trials (585) 585
medicine, general & internal (582) 582
analysis (578) 578
management (567) 567
insulin - adverse effects (564) 564
hypoglycemia - chemically induced (557) 557
health aspects (554) 554
patients (549) 549
insulin resistance (547) 547
drug administration schedule (512) 512
glycated hemoglobin a - analysis (507) 507
drug therapy, combination (495) 495
risk (488) 488
diabetes mellitus - drug therapy (485) 485
blood glucose - analysis (479) 479
dextrose (472) 472
efficacy (472) 472
animals (471) 471
insulin, long-acting - therapeutic use (468) 468
blood sugar (466) 466
open-label (465) 465
adolescent (461) 461
mortality (453) 453
safety (450) 450
dosage and administration (440) 440
glycosylated hemoglobin (440) 440
studies (427) 427
diabetes mellitus, type 2 - complications (425) 425
diabetes mellitus, type 1 - blood (416) 416
endocrinology (416) 416
double-blind (414) 414
type 2 diabetes mellitus (411) 411
hypoglycemic agents (404) 404
review (386) 386
diabetics (365) 365
metformin - therapeutic use (351) 351
hypoglycemia - prevention & control (349) 349
pharmaceutical industry (347) 347
glucagon-like peptide-1 (337) 337
exenatide (331) 331
retrospective studies (328) 328
body mass index (327) 327
hypoglycemic agents - pharmacology (322) 322
liraglutide (320) 320
child (319) 319
peptides (319) 319
obesity (308) 308
insulin detemir (307) 307
randomized controlled trials as topic (307) 307
glucagon (304) 304
diabetes mellitus, type 2 - metabolism (295) 295
metabolism (294) 294
glucose control (291) 291
medical research (288) 288
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6617) 6617
German (73) 73
Spanish (23) 23
French (18) 18
Japanese (17) 17
Czech (10) 10
Chinese (5) 5
Portuguese (5) 5
Hungarian (4) 4
Korean (4) 4
Dutch (3) 3
Italian (3) 3
Swedish (3) 3
Arabic (2) 2
Russian (2) 2
Turkish (2) 2
Bosnian (1) 1
Bulgarian (1) 1
Norwegian (1) 1
Polish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2015, Volume 17, Issue 4, pp. 386 - 394
Journal Article
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 2009, Volume 32, Issue 5, pp. 762 - 768
OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with... 
NON-INFERIORITY | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | BASAL INSULIN | GLUCOSE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | TWICE-DAILY EXENATIDE | Metformin - therapeutic use | C-Peptide - blood | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Exenatide | Female | Insulin - analogs & derivatives | Insulin Secretion | Body Mass Index | Hypoglycemic Agents - therapeutic use | Insulin-Secreting Cells - physiology | Insulin, Long-Acting | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Insulin Glargine | Arginine - pharmacology | Venoms - therapeutic use | Kinetics | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Peptides - therapeutic use | Index Medicus | Original Research | Hemoglobin A | Insulin/analogs & derivatives/secretion/therapeutic use | Blood Glucose/metabolism | Type 2/blood/drug therapy/physiopathology | MEDICIN OCH HÄLSOVETENSKAP | Diabetes Mellitus | Insulin-Secreting Cells/drug effects/physiology | Venoms/therapeutic use | Metformin/therapeutic use | Glycosylated/metabolism | Peptides/therapeutic use | Arginine/pharmacology | Hypoglycemic Agents/therapeutic use | C-Peptide/blood | MEDICAL AND HEALTH SCIENCES
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2016, Volume 18, Issue 2, pp. 159 - 168
Aims To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin... 
insulin antibody | biosimilar insulin | insulin glargine | LY2963016 insulin glargine | Insulin glargine | Insulin antibody | Biosimilar insulin | CONTROLLED-TRIAL | RESPONSES | EFFICACY | SAFETY | ENDOCRINOLOGY & METABOLISM | NAIVE | Immunogenetic Phenomena - drug effects | Recombinant Proteins - therapeutic use | Insulin, Regular, Human - genetics | Humans | Diabetes Mellitus, Type 1 - complications | Insulin Antibodies - analysis | Recombinant Proteins - adverse effects | Incidence | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - immunology | Diabetes Mellitus, Type 1 - immunology | Drug Hypersensitivity - complications | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Drug Hypersensitivity - etiology | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Biosimilar Pharmaceuticals - therapeutic use | Insulin Glargine - adverse effects | Double-Blind Method | Insulin Glargine - therapeutic use | Asymptomatic Diseases - epidemiology | Insulin, Regular, Human - adverse effects | Insulin, Regular, Human - analogs & derivatives | Insulin, Regular, Human - therapeutic use | Biosimilar Pharmaceuticals - adverse effects | Diabetes Mellitus, Type 1 - drug therapy | Cross Reactions | Insulin Glargine - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Drug Hypersensitivity - epidemiology | Drug Hypersensitivity - immunology | Diabetes Mellitus, Type 1 - blood | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Comparative analysis | Insulin | Original
Journal Article
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 366 - 374
Aims To compare the efficacy and safety of insulin glargine 300 U/ml (Gla‐300) with glargine 100 U/ml (Gla‐100) in Japanese people with type 2 diabetes using... 
basal insulin | glycaemic control | type 2 diabetes | insulin analogues | randomized trial | phase III study | Phase III study | Type 2 diabetes | Insulin analogues | Randomized trial | Basal insulin | Glycaemic control | GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | MELLITUS | PROVIDES | UNITS/ML | Glycated Hemoglobin A - analysis | Japan - epidemiology | Hypoglycemia - epidemiology | Follow-Up Studies | Drug Resistance, Multiple | Humans | Middle Aged | Insulin Detemir - therapeutic use | Male | Risk | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Hypoglycemic Agents - administration & dosage | Insulin Detemir - adverse effects | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Insulin Glargine - adverse effects | Administration, Oral | Insulin Glargine - therapeutic use | Diabetes Mellitus, Type 2 - blood | Delayed-Action Preparations - adverse effects | Delayed-Action Preparations - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Hemoglobin | Glucose | Insulin | Dextrose | Diabetes therapy | Confidence intervals | Diabetes | Hypoglycemia | Body mass index | Diabetes mellitus | Diabetes mellitus (non-insulin dependent) | Evidence-based medicine | Original
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2015, Volume 17, Issue 12, pp. 1142 - 1149
Journal Article